| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -32.0 | -26.1 |
| Net income | -32.1 | -26.1 |
| EPS (diluted, $ a share) | $-0.29 | $-0.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AURA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aura Biosciences, Inc.: key numbers
- Share price
- $7.22Close, Nov 16
- Market cap
- $751M
- Shares outstanding
- 104.07MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aura Biosciences, Inc.
All →Aura Biosciences Financial Results
Aura Biosciences reported Q3 2026 financial results and provided a clinical update on its Phase 3 CoMpass trial for bel-sar, which remains on track for topline data in 2H 2027. The company also established a new manufacturing relationship with a CDMO to secure designated capacity for bel-sar and confirmed its cash runway extends into the first half of 2029.
“During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development. With all treatment visits completed in the CoMpass trial, our team is focused on ensuring excellence in all elements of the bel-sar program as we advance toward topline pivotal data in the second half of next year and position bel-sar as the first potential vision-preserving front-line therapy for early choroidal melanoma.”
Natalie Holles, Chief Executive Officer of Aura Biosciences
“We are very pleased to enter this new CDMO relationship, which we believe positions bel-sar for regulatory and commercial success as we advance toward topline data and completion of the CoMpass study. Designated capacity is intended to provide us with long-term control over our production scheduling, and we look forward to working with our new partner to advance this important element of the bel-sar program.”
Susan Abu-Absi, Ph.D., Chief Operating Officer of Aura Biosciences